Vivere Oncotherapies
PrivateLast Round
Seed
Jan 13, 2026
Total Funding Raised
$13.21M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Vivere Oncotherapies is a biotechnology company developing targeted immunotherapies that activate the immune system to detect and destroy cancer cells in solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vivere Oncotherapies Comparables
Compare Vivere Oncotherapies with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Theolytics | 78% | |
| KaliVir Immunotherapeutics | 77% | |
| ReIGNITE Therapeutics | 76% |
Vivere Oncotherapies Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Jan 13, 2026 | ||||
| Grant | Sep 5, 2025 |
Key People
Founding team and executive leadership
Vivere Oncotherapies Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Seed, Grant |
| California Innovation Fund | Seed, Pre Seed |
| Freeflow Ventures | Seed, Pre Seed |
| Pillar VC | Seed, Pre Seed |
| Berkeley Frontier Fund | Seed, Pre Seed |
| Alumni Ventures | Seed |
| Kerna Ventures | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 8, 2026
Grew 40% QoQ from 10 to 14 employees.
- Feb 20, 2026
Grew 56% QoQ, from 9 to 14 employees.
Vivere Oncotherapies Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Vivere Oncotherapies's valuation, stock price, and market status.
Is Vivere Oncotherapies a public or private company?
Vivere Oncotherapies is a private company.
What is the current stock price of Vivere Oncotherapies?
Vivere Oncotherapies is a private company with no public stock price. No recent secondary market data is available.
How much is Vivere Oncotherapies worth (valuation)?
Valuation information for Vivere Oncotherapies is not publicly available.
Can I buy Vivere Oncotherapies stock?
Vivere Oncotherapies shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Vivere Oncotherapies's last funding round?
Vivere Oncotherapies's most recent funding round was Seed on January 13, 2026.
Who are the main investors in Vivere Oncotherapies?
Key investors in Vivere Oncotherapies include National Cancer Institute, California Innovation Fund, Freeflow Ventures, Pillar VC, Berkeley Frontier Fund.
Will Vivere Oncotherapies IPO soon?
No public IPO plans have been announced for Vivere Oncotherapies.
How can I track Vivere Oncotherapies secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Vivere Oncotherapies's secondary market activity and sign up for updates.